HighVista Strategies’s Kymera Therapeutics KYMR Stock Holding History

HighVista Strategies’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$428K	Sell	3,731 -54	-1%	-$4.64K	0.1%	144
2026 Q1	$315K	Sell	3,785 -3,050	-45%	-$242K	0.09%	153
2025 Q4	$532K	Sell	6,835 -8,893	-57%	-$601K	0.14%	140
2025 Q3	$890K	Buy	+15,728	New	+$709K	0.22%	129
2025 Q2	–	Sell	-8,733	Closed	-$239K	–	164
2025 Q1	$239K	Hold	8,733	–	–	0.09%	143
2024 Q4	$351K	Sell	8,733 -4,010	-31%	-$181K	0.13%	133
2024 Q3	$603K	Buy	+12,743	New	+$563K	0.21%	112
2023 Q2	–	Sell	-25,530	Closed	-$756K	–	145
2023 Q1	$756K	Buy	+25,530	New	+$823K	0.62%	54
2021 Q3	–	Sell	-18,587	Closed	-$901K	–	132
2021 Q2	$901K	Buy	18,587 +4,646	+33%	+$202K	0.64%	27
2021 Q1	$542K	Sell	13,941 -3,176	-19%	-$191K	0.4%	66
2020 Q4	$1.06M	Buy	+17,117	New	+$835K	0.68%	24

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

HighVista Strategies's KYMR Position: Q2 2026 in Review

HighVista Strategies reduced its Kymera Therapeutics (KYMR) stake by 1.4% in Q2 2026, selling an estimated $4.64K and leaving 3,731 shares worth $428K. The position accounts for 0.1% of the portfolio, ranked #144.

HighVista Strategies first reported a position in KYMR in Q4 2020 and has held it in 11 quarters since. The position peaked at $1.06M in Q4 2020. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

HighVista Strategies held 3,731 shares of Kymera Therapeutics worth $428K as of Q2 2026.
HighVista Strategies sold 54 Kymera Therapeutics shares in Q2 2026, an estimated $4.64K.
Kymera Therapeutics made up 0.1% of HighVista Strategies's portfolio in Q2 2026, its #144 holding.
HighVista Strategies first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 11 quarters since.
HighVista Strategies's Kymera Therapeutics position peaked at $1.06M in Q4 2020.
277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.